Skip to main content
OpenTrials
Completed

NCT Number: NCT03465501

Interstitial Brachytherapy Boost for Treatment of Anal Canal Cancers, Comparison of Two Dose Rates

Comparative retrospective study of two anal canal brachytherapy techniques aimed at boosting [low dose rate (LDR) and high dose rate (HDR)]

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anal Canal Cancer Anal Canal Carcinoma

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Institut Paoli Calmettes

Marseille, Bouches Du Rhone, 13009, France

About this study

Efficacy of anal canal interstitial brachytherapy evaluated by local relapse rate, Tolerance of interstitial brachytherapy of the anal canal evaluated by the rate of chronic toxicities.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients treated by brachytherapy anal canal to boost.

Exclusion criteria

  • Patients below age of 18 years

Treatment and study plan

Brachytherapy

Radiation

Brachytherapy

Primary outcomes

  1. Evaluation of the efficacy of interstitial brachytherapy of the anal canal

    Time frame: 1 year

    Efficacy of anal canal interstitial brachytherapy evaluated by local relapse rate

  2. Evaluation of the tolerance of interstitial brachytherapy of the anal canal

    Time frame: 1 year

    Tolerance of interstitial brachytherapy of the anal canal evaluated by the rate of chronic toxicities.

Secondary outcomes

  1. Estimation of local control

    Time frame: 1 year

    Local control defined as the time between the date of diagnosis and the date of local relapse or death or recent news

  2. Estimation of disease free survival

    Time frame: 1 year

    Disease free survival defined as the delay between the date of diagnosis and the date of local or locoregional or distant relapse or death or recent news

  3. Estimation of overall survival

    Time frame: 1 year

    Overall survival defined as the time between the date of diagnosis and the date of death or latest news

  4. Comparison of the incidence of toxicities (CTCAE v4) between the 2 groups

    Time frame: 1 year

    rate of toxicities

Sponsors and collaborators

Lead sponsor

Institut Paoli-Calmettes

Other

Registry information

Acronym: BOOST-CA

Important dates

Study start
2007
Primary completion
2016
Study completion
2016
First posted
Mar 14, 2018
Registry last updated
Mar 14, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.